{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:05:47Z","timestamp":1793642747773,"version":"4.5.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T00:00:00Z","timestamp":1548028800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1038\/s41591-018-0312-3","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T12:53:10Z","timestamp":1547038390000},"page":"292-300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":156,"title":["Small-molecule targeting of brachyury transcription factor addiction in chordoma"],"prefix":"10.1038","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7274-164X","authenticated-orcid":false,"given":"Tanaz","family":"Sharifnia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias J.","family":"Wawer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Yuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Sizemore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Lawlor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Goodale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0526-0616","authenticated-orcid":false,"given":"Glenn S.","family":"Cowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2857-4685","authenticated-orcid":false,"given":"Francisca","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slim","family":"Sassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Cogswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadley E.","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinghu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5354-7403","authenticated-orcid":false,"given":"Nathanael S.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9342-1290","authenticated-orcid":false,"given":"Paul A.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Blagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Workman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Hornicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Root","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2718-4415","authenticated-orcid":false,"given":"James E.","family":"Bradner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwok K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9155-090X","authenticated-orcid":false,"given":"Charles Y.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1915-1605","authenticated-orcid":false,"given":"Joanne D.","family":"Kotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1922-7558","authenticated-orcid":false,"given":"Stuart L.","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,21]]},"reference":[{"key":"312_CR1","unstructured":"Stacchiotti, S., Sommer, J. & Chordoma Global Consensus Group. Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet. Oncol. 16, e71\u2013e83 (2015)."},{"key":"312_CR2","doi-asserted-by":"publisher","first-page":"e101283","DOI":"10.1371\/journal.pone.0101283","volume":"9","author":"E Choy","year":"2014","unstructured":"Choy, E. et al. Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1. PLoS ONE 9, e101283 (2014).","journal-title":"PLoS ONE"},{"key":"312_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01026-0","volume":"8","author":"PS Tarpey","year":"2017","unstructured":"Tarpey, P. S. et al. The driver landscape of sporadic chordoma. Nat. Commun. 8, 890 (2017).","journal-title":"Nat. Commun."},{"key":"312_CR4","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nature13393","volume":"511","author":"N Kwiatkowski","year":"2014","unstructured":"Kwiatkowski, N. et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 511, 616\u2013620 (2014).","journal-title":"Nature"},{"key":"312_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","volume":"168","author":"JE Bradner","year":"2017","unstructured":"Bradner, J. E., Hnisz, D. & Young, R. A. Transcriptional addiction in cancer. Cell. 168, 629\u2013643 (2017).","journal-title":"Cell."},{"key":"312_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/A:1008947301735","volume":"12","author":"ML McMaster","year":"2001","unstructured":"McMaster, M. L., Goldstein, A. M., Bromley, C. M., Ishibe, N. & Parry, D. M. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 12, 1\u201311 (2001).","journal-title":"Cancer Causes Control"},{"key":"312_CR7","doi-asserted-by":"crossref","unstructured":"Barry, J. J. et al. The next step: innovative molecular targeted therapies for treatment of intracranial chordoma patients. Neurosurgery 68, 231\u2013240 (2011). discussion 240\u2013231.","DOI":"10.1227\/NEU.0b013e3181fd2ac5"},{"key":"312_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/path.1711710404","volume":"171","author":"JR Salisbury","year":"1993","unstructured":"Salisbury, J. R. The pathology of the human notochord. J. Pathol. 171, 253\u2013255 (1993).","journal-title":"J. Pathol."},{"key":"312_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/path.1969","volume":"209","author":"S Vujovic","year":"2006","unstructured":"Vujovic, S. et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J. Pathol. 209, 157\u2013165 (2006).","journal-title":"J. Pathol."},{"key":"312_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/dvdy.10480","volume":"229","author":"C Showell","year":"2004","unstructured":"Showell, C., Binder, O. & Conlon, F. L. T-box genes in early embryogenesis. Dev. Dyn. 229, 201\u2013218 (2004).","journal-title":"Dev. Dyn."},{"key":"312_CR11","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/ng.454","volume":"41","author":"XR Yang","year":"2009","unstructured":"Yang, X. R. et al. T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat. Genet. 41, 1176\u20131178 (2009).","journal-title":"Nat. Genet."},{"key":"312_CR12","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/ng.2419","volume":"44","author":"N Pillay","year":"2012","unstructured":"Pillay, N. et al. A common single-nucleotide variant in T is strongly associated with chordoma. Nat. Genet. 44, 1185\u20131187 (2012).","journal-title":"Nat. Genet."},{"key":"312_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/path.2816","volume":"223","author":"N Presneau","year":"2011","unstructured":"Presneau, N. et al. Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. J. Pathol. 223, 327\u2013335 (2011).","journal-title":"J. Pathol."},{"key":"312_CR14","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3171\/2011.5.JNS11185","volume":"115","author":"W Hsu","year":"2011","unstructured":"Hsu, W. et al. Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target. J. Neurosurg. 115, 760\u2013769 (2011).","journal-title":"J. Neurosurg."},{"key":"312_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.celrep.2017.09.057","volume":"21","author":"SR Shah","year":"2017","unstructured":"Shah, S. R. et al. Brachyury-YAP regulatory axis drives stemness and growth in cancer. Cell Rep. 21, 495\u2013507 (2017).","journal-title":"Cell Rep."},{"key":"312_CR16","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-06-2353","volume":"13","author":"C Palena","year":"2007","unstructured":"Palena, C. et al. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin. Cancer Res. 13, 2471\u20132478 (2007).","journal-title":"Clin. Cancer Res."},{"key":"312_CR17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/nrc1947","volume":"6","author":"LA Garraway","year":"2006","unstructured":"Garraway, L. A. & Sellers, W. R. Lineage dependency and lineage-survival oncogenes in human cancer. Nat. Rev. Cancer 6, 593\u2013602 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"312_CR18","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.cbpa.2008.07.023","volume":"12","author":"T Berg","year":"2008","unstructured":"Berg, T. Inhibition of transcription factors with small organic molecules. Curr. Opin. Chem. Biol. 12, 464\u2013471 (2008).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"312_CR19","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.chembiol.2017.08.002","volume":"24","author":"T Sharifnia","year":"2017","unstructured":"Sharifnia, T., Hong, A. L., Painter, C. A. & Boehm, J. S. Emerging opportunities for target discovery in rare cancers. Cell Chem. Biol. 24, 1075\u20131091 (2017).","journal-title":"Cell Chem. Biol."},{"key":"312_CR20","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/ng.3984","volume":"49","author":"RM Meyers","year":"2017","unstructured":"Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779\u20131784 (2017).","journal-title":"Nat. Genet."},{"key":"312_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ydbio.2006.03.014","volume":"295","author":"F Barrionuevo","year":"2006","unstructured":"Barrionuevo, F., Taketo, M. M., Scherer, G. & Kispert, A. Sox9 is required for notochord maintenance in mice. Dev. Biol. 295, 128\u2013140 (2006).","journal-title":"Dev. Biol."},{"key":"312_CR22","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1158\/2159-8290.CD-15-0235","volume":"5","author":"B Seashore-Ludlow","year":"2015","unstructured":"Seashore-Ludlow, B. et al. Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov. 5, 1210\u20131223 (2015).","journal-title":"Cancer Discov."},{"key":"312_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.02.008","volume":"173","author":"SR Whittaker","year":"2017","unstructured":"Whittaker, S. R., Mallinger, A., Workman, P. & Clarke, P. A. Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol. Ther. 173, 83\u2013105 (2017).","journal-title":"Pharmacol. Ther."},{"key":"312_CR24","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/nchembio.2166","volume":"12","author":"T Zhang","year":"2016","unstructured":"Zhang, T. et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat. Chem. Biol. 12, 876\u2013884 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"312_CR25","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.molcel.2015.09.001","volume":"60","author":"GG Galli","year":"2015","unstructured":"Galli, G. G. et al. YAP drives growth by controlling transcriptional pause release from dynamic enhancers. Mol. Cell 60, 328\u2013337 (2015).","journal-title":"Mol. Cell"},{"key":"312_CR26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00210-014-0967-3","volume":"387","author":"H Modjtahedi","year":"2014","unstructured":"Modjtahedi, H., Cho, B. C., Michel, M. C. & Solca, F. A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn Schmiedebergs Arch. Pharmacol. 387, 505\u2013521 (2014).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"312_CR27","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/path.4729","volume":"239","author":"S Scheipl","year":"2016","unstructured":"Scheipl, S. et al. EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. J. Pathol. 239, 320\u2013334 (2016).","journal-title":"J. Pathol."},{"key":"312_CR28","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1158\/1078-0432.CCR-16-3157","volume":"23","author":"D Tripathy","year":"2017","unstructured":"Tripathy, D., Bardia, A. & Sellers, W. R. Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4\/6 inhibitor in various solid tumors. Clin. Cancer Res. 23, 3251\u20133262 (2017).","journal-title":"Clin. Cancer Res."},{"key":"312_CR29","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nchembio.1952","volume":"11","author":"T Dale","year":"2015","unstructured":"Dale, T. et al. A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. Nat. Chem. Biol. 11, 973\u2013980 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"312_CR30","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/nchembio.2458","volume":"13","author":"L. Johannessen","year":"2017","unstructured":"Johannessen, L. et al. Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells. Nat. Chem. Biol. 13, 1102\u20131108 (2017).","journal-title":"Nat. Chem. Biol."},{"key":"312_CR31","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Loven","year":"2013","unstructured":"Loven, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320\u2013334 (2013).","journal-title":"Cell"},{"key":"312_CR32","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","volume":"155","author":"D Hnisz","year":"2013","unstructured":"Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934\u2013947 (2013).","journal-title":"Cell"},{"key":"312_CR33","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/path.4082","volume":"228","author":"AC Nelson","year":"2012","unstructured":"Nelson, A. C. et al. An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma. J. Pathol. 228, 274\u2013285 (2012).","journal-title":"J. Pathol."},{"key":"312_CR34","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/nmeth.2688","volume":"10","author":"JD Buenrostro","year":"2013","unstructured":"Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods 10, 1213\u20131218 (2013).","journal-title":"Nat. Methods"},{"key":"312_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature16546","volume":"530","author":"CY Lin","year":"2016","unstructured":"Lin, C. Y. et al. Active medulloblastoma enhancers reveal subgroup-specific cellular origins. Nature 530, 57\u201362 (2016).","journal-title":"Nature"},{"key":"312_CR36","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00262-008-0557-7","volume":"58","author":"JH Schwab","year":"2009","unstructured":"Schwab, J. H. et al. Chordoma and chondrosarcoma gene profile: implications for immunotherapy. Cancer Immunol. Immunother. 58, 339\u2013349 (2009).","journal-title":"Cancer Immunol. Immunother."},{"key":"312_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02174-5","volume":"7","author":"D Jager","year":"2017","unstructured":"Jager, D. et al. HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas. Sci. Rep. 7, 2032 (2017).","journal-title":"Sci. Rep."},{"key":"312_CR38","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/path.2818","volume":"223","author":"A Shalaby","year":"2011","unstructured":"Shalaby, A. et al. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J. Pathol. 223, 336\u2013346 (2011).","journal-title":"J. Pathol."},{"key":"312_CR39","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1073\/pnas.85.5.1417","volume":"85","author":"DK Trask","year":"1988","unstructured":"Trask, D. K. & Muller, M. T. Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc. Natl Acad. Sci. USA 85, 1417\u20131421 (1988).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"312_CR40","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/jor.22113","volume":"30","author":"X Liu","year":"2012","unstructured":"Liu, X. et al. Establishment and characterization of a novel chordoma cell line: CH22. J. Orthop. Res. 30, 1666\u20131673 (2012).","journal-title":"J. Orthop. Res."},{"key":"312_CR41","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"312_CR42","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/nbt.3026","volume":"32","author":"JG Doench","year":"2014","unstructured":"Doench, J. G. et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat. Biotechnol. 32, 1262\u20131267 (2014).","journal-title":"Nat. Biotechnol."},{"key":"312_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2014.35","volume":"1","author":"GS Cowley","year":"2014","unstructured":"Cowley, G. S. et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci. Data 1, 140035 (2014).","journal-title":"Sci. Data"},{"key":"312_CR44","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1158\/2159-8290.CD-16-0154","volume":"6","author":"AJ Aguirre","year":"2016","unstructured":"Aguirre, A. J. et al. Genomic copy number dictates a ene-independent cell response to CRISPR\/Cas9 targeting. Cancer Discov. 6, 914\u2013929 (2016).","journal-title":"Cancer Discov"},{"key":"312_CR45","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","volume":"8","author":"WE Johnson","year":"2007","unstructured":"Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118\u2013127 (2007).","journal-title":"Biostatistics"},{"key":"312_CR46","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84\u201387 (2014).","journal-title":"Science"},{"key":"312_CR47","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1177\/1087057113520226","volume":"19","author":"V Dancik","year":"2014","unstructured":"Dancik, V. et al. Connecting small molecules with similar assay performance profiles leads to new biological hypotheses. J. Biomol. Screen. 19, 771\u2013781 (2014).","journal-title":"J. Biomol. Screen."},{"key":"312_CR48","first-page":"15","volume-title":"Bioinformatics","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013)."},{"key":"312_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome. Biol. 15, 550 (2014).","journal-title":"Genome. Biol."},{"key":"312_CR50","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"312_CR51","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267\u2013273 (2003).","journal-title":"Nat. Genet."},{"key":"312_CR52","first-page":"10 11","volume":"43","author":"GA Auwera Van der","year":"2013","unstructured":"Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinformatics 43, 10 11\u201310 33 (2013).","journal-title":"Curr. Protoc. Bioinformatics"},{"key":"312_CR53","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"312_CR54","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303 (2010).","journal-title":"Genome Res."},{"key":"312_CR55","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"312_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2008-9-9-r137","volume":"9","author":"Y Zhang","year":"2008","unstructured":"Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome. Biol. 9, R137 (2008).","journal-title":"Genome. Biol."},{"key":"312_CR57","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.molcel.2014.08.024","volume":"56","author":"JD Brown","year":"2014","unstructured":"Brown, J. D. et al. NF-\u03baB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol. Cell 56, 219\u2013231 (2014).","journal-title":"Mol. Cell"},{"key":"312_CR58","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/nature09627","volume":"468","author":"CM Johannessen","year":"2010","unstructured":"Johannessen, C. M. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968\u2013972 (2010).","journal-title":"Nature"},{"key":"312_CR59","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","volume":"26","author":"AR Quinlan","year":"2010","unstructured":"Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841\u2013842 (2010).","journal-title":"Bioinformatics"},{"key":"312_CR60","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","volume":"38","author":"S Heinz","year":"2010","unstructured":"Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576\u2013589 (2010).","journal-title":"Mol. Cell"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41591-018-0312-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-018-0312-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-018-0312-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:58:22Z","timestamp":1684605502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-018-0312-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,21]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["312"],"URL":"https:\/\/doi.org\/10.1038\/s41591-018-0312-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,21]]},"assertion":[{"value":"22 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.S. is a consultant for Jnana Therapeutics. N.S.G. is equity holder and scientific advisor for Syros, Gatekeeper, Soltego, C4, Petra, and Aduro companies. Syros has licensed intellectual property from Dana-Farber Cancer Institute covering THZ1. P.A. Clarke, J.B., and P.W. are current employees of The Institute of Cancer Research, which has a Rewards to Inventors scheme and has a commercial interest in the development of inhibitors of the WNT pathway, CDK8\/19, and other CDKs, with intellectual property licensed to Merck and Cyclacel Pharmaceuticals. P.W. is a consultant for Astex Pharmaceuticals, CV6 Therapeutics, Nextechinvest, Nuevolution, and Storm Therapeutics and holds equity in Chroma Therapeutics, Nextech, and Storm. D.E.R. receives research funding from members of the Functional Genomics Consortium (Abbvie, Jannsen, Merck, Vir), and is a director of Addgene, Inc. W.C.H. is a consultant for Thermo Fisher, Paraxel, AjuIB, MPM Capital, and KSQ Therapeutics, a founder of KSQ Therapeutics, and receives research support from Deerfield. J.E.B. is now an executive and shareholder of Novartis AG, and has been a founder and shareholder of SHAPE (acquired by Medivir), Acetylon (acquired by Celgene), Tensha (acquired by Roche), Syros, Regency, and C4 Therapeutics. K.K.W. is a founder and equity holder of G1 Therapeutics and he has consulting\/sponsored research agreements with AstraZeneca, Janssen, Pfizer, Array, Novartis, Merck, Takeda, Ono, Targimmune, and BMS. C.Y.L. is a consultant for Jnana Therapeutics and is a shareholder of and inventor of intellectual property licensed to Syros Pharmaceuticals. J.D.K. is a founder, executive and shareholder of Jnana Therapeutics. S.L.S. is a member of the Board of Directors of the Genomics Institute of the Novartis Research Foundation (GNF); a shareholder and member of the Board of Directors of Jnana Therapeutics; a shareholder of Forma Therapeutics; a shareholder of and adviser to Decibel Therapeutics; an adviser to Eisai, Inc., the Ono Pharma Foundation, and F-Prime Capital Partners; and a Novartis Faculty Scholar. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}